Merck Enters Cancer Vaccine Collaboration With Geron
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck acquires expertise in telomerase-targeting cancer vaccines in a deal with Menlo Park, Calif.-based Geron. Under the agreement, Geron will receive an upfront payment, milestone payments and royalties. Merck also gains the option to partner on Geron’s investigational prostate cancer vaccine.
You may also be interested in...
Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans
FDA lifted its clinical hold on Geron’s human embryonic stem cell therapy for spinal-cord injury, granting the company’s IND application and creating a hallelujah moment for frustrated believers in embryonic stem cell medicine.
Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans
FDA lifted its clinical hold on Geron’s human embryonic stem cell therapy for spinal-cord injury, granting the company’s IND application and creating a hallelujah moment for frustrated believers in embryonic stem cell medicine.
Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans
After being delayed since May, Geron’s 21,000-page application clears overnight in the first week of the Obama administration.